Loading company…
SEKISUI XenoTech conducts nonclinical drug metabolism and drug interaction studies.
Founded in 1994 and based in Kansas, US, SEKISUI XenoTech, also known as XenoTech, provides contract research for pharmaceutical companies. Its work covers absorption, distribution, metabolism and excretion, pharmacokinetics and drug-drug interactions, as well as consulting, radiolabeling, bioanalysis and test systems. The company was established by Dr. Andrew Parkinson and was led by CEO Darren Warren as of 2022. In September 2022, BioIVT, a portfolio company of Arsenal Capital Partners and Linden, acquired it from Sekisui Chemical Co., Ltd.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in